M

MaxCyte Inc
NASDAQ:MXCT

Watchlist Manager
MaxCyte Inc
NASDAQ:MXCT
Watchlist
Price: 1.23 USD 1.65% Market Closed
Market Cap: 131.2m USD

Gross Margin

80%
Current
Declining
by 5.4%
vs 3-y average of 85.4%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
80%
=
Gross Profit
$27.5m
/
Revenue
$34.4m

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
80%
=
Gross Profit
$27.5m
/
Revenue
$34.4m

Peer Comparison

Country Company Market Cap Gross
Margin
US
MaxCyte Inc
NASDAQ:MXCT
131.2m USD
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
240.3B USD
Loading...
US
Danaher Corp
NYSE:DHR
171B USD
Loading...
CH
Lonza Group AG
SIX:LONN
38.3B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
41.1B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
278.3B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
39.6B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
83T KRW
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
29.5B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
19.8B EUR
Loading...
No Stocks Found

Market Distribution

Higher than 89% of companies in the United States of America
Percentile
89th
Based on 12 729 companies
89th percentile
80%
Low
-24 813% — 28.9%
Typical Range
28.9% — 60.5%
High
60.5% — 10 905 714.3%
Distribution Statistics
the United States of America
Min -24 813%
30th Percentile 28.9%
Median 43%
70th Percentile 60.5%
Max 10 905 714.3%

MaxCyte Inc
Glance View

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.

MXCT Intrinsic Value
2.59 USD
Undervaluation 53%
Intrinsic Value
Price
M
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
80%
=
Gross Profit
$27.5m
/
Revenue
$34.4m
What is MaxCyte Inc's current Gross Margin?

The current Gross Margin for MaxCyte Inc is 80%, which is below its 3-year median of 85.4%.

How has Gross Margin changed over time?

Over the last 3 years, MaxCyte Inc’s Gross Margin has decreased from 88.6% to 80%. During this period, it reached a low of 79.8% on Jun 30, 2025 and a high of 88.6% on Aug 30, 2022.

Back to Top